tbuckley/cabot-search huggingface dataset:
Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma (CS)
Authors: H. Gelderblom, P. Hohenberger, J. V. Bovee, A. M. Cleton-Jansen, P. Stroebel, D. Meijer, A. H. Taminiau, P. C. Hogendoorn
Journal: Journal of Clinical Oncology (2008)

10542 Background: Surgery is the only effective treatment for CS, as this disease is considered chemotherapy and radiotherapy resistant. Therefore new treatment options are warranted for irresectable recurrent or metastatic disease. We have shown previously that estrogen signaling is active in CS and estrogen and its precursor androstenedione promote growth of CS cells in vitro which can be inhibited by aromatase inhibition. Methods: Patients with irresectable recurrent and/or metastatic CS that were treated with an aromatase inhibitor in the past 5 years at 2 centers. Radiological evaluations were performed every 2–3 months. Available pathology specimens were analyzed for expression of the estrogen/progesterone receptor and aromatase activity. Results: Ten patients were included: 5 male and 5 female, age 33–68y (median 46y), 9 conventional CS and 1 dedifferentiated CS. Primary localization was pelvic (6), thoracic wall (1), femur (1), humerus (1) and spine (1). All but 2 patients had recurrent disease, 4 in combination with metastatic disease and the remaining 2 patients had either metastatic disease only or in combination with primary disease. Aromatase inhibitors being used were letrozole (4), anastrozole (4) and exemestane (2). All patients had progressive disease upon initiation of therapy. Of the 7 evaluable patients the median time to progression (TTP) for the primary was 6 months (range 4–31 months). For the metastatic tumors the median TTP was 9 months (2–14+ months), including the dedifferentiated CS with TTP of 2 months. Correlation with tumor characteristics, such as hormone receptor status, grade and aromatase activity, are analyzed. Conclusions: Aromatase inhibition seems to yield some activity in conventional CS; especially in metastatic disease. Based on this pilot series, a formal phase II study in metastatic conventional CS is warranted. No significant financial relationships to disclose.
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.
Authors: Heinz Ludwig, Luisa Viterbo, Richard Greil, Tamas Masszi, Ivan Spicka, Ofer Shpilberg, Roman Hajek, Anna Dmoszynska, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean-Luc Harousseau
Journal: Blood (2009)
Transcriptome Profiling of Lenalidomide Treated Myeloma Patients Identifies an Interferon Signature Gene Response and a Novel IRF4/MYC Independent Mechanism of Resistance
Authors: Paola E. Neri, Ines Tagoug, Li Ren, Ranjan Maity, Justin Simms, Peter Duggan, Victor H Jimenez-Zepeda, Jiri Slaby, Howie Wu, Jackie Babich, Nizar J Bahlis
Journal: Blood (2014)
Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study)
Authors: Silvia Calviño Günther, Carole Schwebel, Rebecca Hamidfar-Roy, Agnès Bonadona, Maxime Lugosi, Claire Ara-Somohano, Clémence Minet, Leïla Potton, Jean-Charles Cartier, Aurelien Vésin, Magalie Chautemps, Lenka Styfalova, Stephane Ruckly, Jean-François Timsit
Journal: Intensive Care Medicine (2016)
TCT-385 Safety and Feasibility of Rotational Atherectomy in Octogenarians with Severe Aortic Stenosis and Calcific Coronary Artery Disease undergoing Evaluation for Transcatheter Aortic Valve Replacement: A Retrospective Observational Analysis
Authors: Falak Shah, Amir Darki, Bruce E. Lewis, Leya Ferdinand, John J. Lopez, Lowell H. Steen
Journal: Journal of the American College of Cardiology (2015)
Preliminary Results of a Prospective Multicenter Phase III Trial Comparing High-Dose and Standard-Dose Daunorubicin for Induction of Complete Remission (CR) in Acute Myeloid Leukemia (AML).
Authors: Je-Hwan Lee, Young-Don Joo, Jae-Hoo Park, Hun Mo Ryoo, Myung Soo Hyun, Dae Young Zang, Jin Seok Ahn, Junglim Lee, Kyeong Won Lee, Seong-Jun Choi, Jung-Hee Lee, Miee Seol, Keun-Hee Kim, Won-Sik Lee, Young Joo Min, Hawk Kim, Sung-Hwa Bae, Min Kyung Kim, Hyo Jung Kim, Kyoo-Hyung Lee
Journal: Blood (2007)
Monocyte-Derived Dendritic Cells Pulsed with Aspergillus Fumigatus Components Enhance the Anti-Aspergillus Effect of Human Natural Killer Cells
Authors: Maria Bouzani, Anna Lena Schmitt, Vishu Aimanianda, Christin Flechsig, Sen Mui Tan, Götzi Ulrich Grigoleit, Jean Paul Latge, Hermann Einsele, Juergen Loeffler
Journal: Blood (2011)
Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.
Authors: Tary Traore, James J. Garnsey, Erik Koenig, Allison J Berger, Mark G Manfredi, Lilli Petruzzelli, Peter G. Smith
Journal: Blood (2009)
Extended Platelet In Vivo Survival Results in Exhausted Platelets
Authors: Irina Pleines, Marion Lebois, Amanda E.-L. Au, Rachael M. Lane, Katya J. Henley, Jason Corbin, Ping Cannon, Kate E Jarman, Sarah Ellis, Shaun P Jackson, Simone M. Schoenwaelder, Benjamin T. Kile, Emma C. Josefsson
Journal: Blood (2015)
Left Ventricular Noncontact Mapping In Humans With Cardiomyopathy: Mechanistic Insights for Cardiac Resynchronization Therapy
Authors: Matthew Ginks, Pier Lambiase, Phani Chinchapatnam, Kawal Rhode, Julian Bostock, Maretha Navue, Stephen Sinclair, Cliff Bucknall, Reza Razavi, C. Aldo Rinaldi
Journal: Journal of the American College of Cardiology (2009)
Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)
Authors: Hagop M Kantarjian, Susan O’Brien, Farhad Ravandi, Jorge Cortes, Jianqin Shan, John M. Bennett, Alan F. List, Pierre Fenaux, Guillermo Garcia-Manero
Journal: Blood (2008)
Harry Reid to Retire
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-338 Head-to-Head Comparison of Two Commercially Available Automated Detection Algorithms for Lumen Contour in Optical Coherence Tomography Analysis
Authors: Kyuhachi Otagiri, Hideki Kitahara, Shigemitsu Tanaka, Kozo Okada, Yuhei Kobayashi, Takashi Miura, Soichiro Ebisawa, Yusuke Miyashita, Hiroshi Kitabayashi, Paul Yock, Peter J. Fitzgerald, Uichi Ikeda, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2015)
CircRNAs in hematopoiesis and hematological malignancies
Authors: A Bonizzato, E Gaffo, G te Kronnie, S Bortoluzzi
Journal: Blood Cancer Journal (2016)

Abstract Cell states in hematopoiesis are controlled by master regulators and by complex circuits of a growing family of RNA species impacting cell phenotype maintenance and plasticity. Circular RNAs (circRNAs) are rapidly gaining the status of particularly stable transcriptome members with distinctive qualities. RNA-seq identified thousands of circRNAs with developmental stage- and tissue-specific expression corroborating earlier suggestions that circular isoforms are a natural feature of the cell expression program. CircRNAs are abundantly expressed also in the hematopoietic compartment. There are a number of studies on circRNAs in blood cells, a specific overview is however lacking. In this review we first present current insight in circRNA biogenesis discussing the relevance for hematopoiesis of the highly interleaved processes of splicing and circRNA biogenesis. Regarding molecular functions circRNAs modulate host gene expression, but also compete for binding of microRNAs, RNA-binding proteins or translation initiation and participate in regulatory circuits. We examine circRNA expression in the hematopoietic compartment and in hematologic malignancies and review the recent breakthrough study that identified pathogenic circRNAs derived from leukemia fusion genes. CircRNA high and regulated expression in blood cell types indicate that further studies are warranted to inform the position of these regulators in normal and malignant hematopoiesis.
TCT-26 Balloon Pulmonary Angioplasty Driven By Combined Assessment of Intra-Arterial Anatomy And Physiology In Patients With Non Operable Distal Chronic Thromboembolic Pulmonary Hypertension
Authors: Marek Roik, Dominik Wretowski, Andrzej Łabyk, Katarzyna Irzyk, Maciej Kostrubiec, Piotr Pruszczyk
Journal: Journal of the American College of Cardiology (2015)
TCT-84 Enhanced Circumferential Ablation using a Multi-electrode Bipolar/Unipolar Over-the -Wire Renal Denervation RF Catheter System with Closed Loop Sensing
Authors: Abraham R. Tzafriri, Lynn Bailey, John Keating, Fernando Garcia-Polite, Peter Markham, David Prutchi, Elazer R. Edelman
Journal: Journal of the American College of Cardiology (2015)
The genomic landscape of schwannoma
Authors: Sameer Agnihotri, Shahrzad Jalali, Mark R Wilson, Arnavaz Danesh, Mira Li, George Klironomos, Jonathan R Krieger, Alireza Mansouri, Osaama Khan, Yasin Mamatjan, Natalie Landon-Brace, Takyee Tung, Mark Dowar, Tiantian Li, Jeffrey P Bruce, Kelly E Burrell, Peter D Tonge, Amir Alamsahebpour, Boris Krischek, Pankaj Kumar Agarwalla, Wenya Linda Bi, Ian F Dunn, Rameen Beroukhim, Michael G Fehlings, Vera Bril, Stefano M Pagnotta, Antonio Iavarone, Trevor J Pugh, Kenneth D Aldape, Gelareh Zadeh
Journal: Nature Genetics (2016)
TCT-629 Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Mild Aortic Valve Calcification
Authors: Yigal Abramowitz, Hasan Jilaihawi, Tarun Chakravarty, Mohammad Kashif, Yoshio Kazuno, Yoshio Maeno, Nobuyuki Takahashi, Hiroyuki Kawamori, Rahul P. Sharma, Justin Cox, Wen Cheng, Raj Makkar
Journal: Journal of the American College of Cardiology (2015)
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
Authors: Roy S. Herbst, Paul Baas, Jose Luis Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon
Journal: Journal of Clinical Oncology (2016)

3030 Background: In KEYNOTE-010 (NCT01905657), pembro was superior to doce for OS in patients (pts) with PD-L1–positive advanced NSCLC that progressed after ≥2 platinum-doublet chemotherapy cycles (P = .0002 for 2 mg/kg, P < .0001 for 10 mg/kg for PD-L1 tumor proportion score [TPS] ≥50%; P= .0008 and < .0001 for PD-L1 TPS ≥1%). We compared outcomes in pts enrolled based on PD-L1 in archival vs new tumor samples. Methods: PD-L1 was assessed centrally by IHC (22C3 antibody) in archival or new (ie, no intervening therapy between collection and start of study drug) tumor samples. 1034 pts received pembro 2 or 10 mg/kg Q3W or doce 75 mg/m2Q3W for 24 mo or until progression, intolerable toxicity, or other reason. Response was assessed by RECIST v1.1 every 9 wk. Survival was assessed every 2 mo. Primary end points were OS and PFS in the TPS ≥50% and ≥1% populations. Pembro doses were pooled for this prespecified analysis. Results: Enrollment was based on archival samples in 456 pts (44%) and new samples in 578 (56%). Median (range) time between sample collection and PD-L1 assessment was 250 d (3-2510) and 11 d (1-371), respectively. PD-L1 TPS was ≥50% for 40% of archival and 45% of new samples. Archival samples were used in 48% of 222 pts with squamous and 43% of 724 pts with nonsquamous histology. Pembro significantly improved OS for TPS ≥50% and ≥1% in pts enrolled based on new and archival samples (Table). The PFS benefit pembro vs doce was similar in archival and new samples (Table). Conclusions: Pembro provided superior OS over doce regardless of whether new or archival samples were used to assess PD-L1. Incidence of PD-L1 TPS ≥50% was similar in archival and new samples. These data suggest a new biopsy may not be required for this predictive assay, sparing pts from risks associated with sample collection and avoiding resource utilization. Clinical trial information: NCT01905657.Pembro/Doce TPS ≥50% TPS ≥1% Archival n = 119/65 New n = 171/87 Archival n = 300/155 New n = 390/188 OS Median, mo 11.5/7.5 NR/8.3 10.5/8.3 12.6/8.6 HR (95% CI) 0.60 (0.40-0.90) 0.44 (0.29-0.66) 0.70 (0.54-0.89) 0.64 (0.50-0.83) PFS Median, mo 3.9/4.0 6.3/4.3 2.9/3.8 4.1/4.2 HR (95% CI) 0.64 (0.45-0.90) 0.54 (0.39-0.75) 0.81 (0.65-1.01) 0.86 (0.70-1.07)
Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Authors: Christine Chen, Harminder Paul, Trina Wang, Lisa W Le, Vishal Kukreti, Ellen Nong Wei, Anthea Lau, P. Leif Bergsagel, Nimisha Dave, Suzanne Trudel
Journal: Blood (2012)
TCT-533 Acute and Chronic Recoil Comparison Between Novel Thinner-Strut Sirolimus-Eluting Coronary Scaffold and Regular-Strut Scaffolds in Normal Porcine Coronary Arteries
Authors: Lijie Wang, Pawel Gasior, Yanping Cheng, Edward A. Estrada, Jenn McGregor, Kamal Razipoor, Gaoke Feng, Chang Lee, Gerard B. Conditt, Juan Granada, Greg L. Kaluza
Journal: Journal of the American College of Cardiology (2015)
A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).
Authors: Francis J. Giles, Wendy Stock, Norbert Vey, Karen Seiter, Daniel J. DeAngelo, Darinka Boskovic, Robert K. Stuart, Bonny Johnson, Ann L. Cahill, Susan O’Brien
Journal: Blood (2006)
28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)
Authors: L. Roberts-Rapp, P. Ansell, R. Kular, M. Song, I. Sokolova, H.K. Gan, K.P. Papadopoulos, A.B. Lassman, R. Merrell, P. Kumthekar, A.M. Scott, E. Gomez, J. Fischer, A. Bhathena, K. Holen, R. Lai, D. Reardon, M. van den Bent
Journal: Annals of Oncology (2015)
TCT-717 Prognostic impact, imaging and clinical predictors of mitral regurgitation improvement after TAVI in aortic stenosis patients: A multicentric study
Authors: Ignacio J. Amat-Santos, Carlos Cortes, Luis Nombela-Franco, Antonio J. Munoz-Garcia, Enrique Gutierrez-Ibanes, Juan Gabriel Cordoba Soriano, Carlos Macaya, Jesus Jimenez-Mazuecos, Jose M. De la Torre Hernandez
Journal: Journal of the American College of Cardiology (2015)
Authors’ reply to Tavabie
Authors: Chris Day, Jessica Glen, Lefteris Floros, Rachel Pryke
Journal: BMJ (2016)

In response to the letter from Tavabie,1 2 we chose the 10.51 cut-off for the enhanced liver fibrosis (ELF) test because of the higher quality of evidence available for this threshold than for two others (low quality versus very low …
GW27-e0268 A study on the mechanism of the SIRT1 in Ginsenoside Rb1 against the intrinsic aging of mouse brain
Authors: Bin Zhou, Lin Wu, Yong Liu, Shujie Yu, Dinghui Liu, Min Wang, Yesheng Ling, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
TCT-220 Effect of prasugrel versus clopidogrel in ACS patients with high or low BMI undergoing PCI: Results from the PROMETHEUS Study
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa Aquino, Craig E. Strauss, Joseph B. Muhlestein, Sandra Weiss, Mark B. Effron, Stuart Y. Keller, Brian A. Baker, Jennifer Chao, Sunil Rao, Samir Kapadia, Kanhaiya L. Poddar, Anthony DeFranco, Annapoorna Kini, William Weintraub, Timothy D. Henry, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)
TCT-202 Early Percutaneous Left Heart Discharge Is A Safe And Efficient Strategy To Help Left Ventricular Recovery In Patients Supported By Venoarterial Extracorporeal Membrane Oxygenation
Authors: Alban-Elouen Baruteau, Marc E. Richmond, Philippe Brenot, Emile Bacha, Julie A. Vincent
Journal: Journal of the American College of Cardiology (2015)
Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades
Authors: M Adamiak, A Abdelbaset-Ismail, M Suszynska, A Abdel-Latif, J Ratajczak, M Z Ratajczak
Journal: Leukemia (2016)

Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades
PROCHE: A program to improve the organization of a medical oncology outpatient unit.
Authors: M. Berhoune, F. Scotte, H. Aboudagga, J. Fouque, S. Marsan, C. Nedelec, J. Stevens, P. Prognon, S. Oudard, B. Bonan
Journal: Journal of Clinical Oncology (2010)

e16548 Background: A pilot program (PROCHE : Chemotherapy Optimization Program) to pre-emptively confirm scheduled chemotherapy treatment by collecting patient (pt) safety data was conducted. One aim was to optimize the organization of our medical oncology outpatient unit. Methods: Clinical and biological data for each pt were collected two days prior to each scheduled in-hospital chemotherapy treatment by nurses (based in a specialiazed call center) who used a questionnaire. The day before treatment, oncologists confirmed, postponed or cancelled the treatment based on these data. If confirmed, the hospital pharmacy prepared the chemotherapy drugs a day in advance. Study endpoints assessed before and during the program, using student's t test, were: mean time spent by pts in the hospital on the day of their visit (pt time), cost of unused prepared chemotherapy drugs, and reallocation of vacant seats in the medical oncology outpatient unit. Results: Between October of 2008 and Oct 2009, 593 pts participated in the program of whom 86% had at least two completed questionnaires. Mean ‘pt time' was significantly (p < 0.001) reduced from 247 to 203 minutes, representing a mean gain of 44 ± 10 minutes per patient. In the month prior to the program, 16 of 1,795 preparations were destroyed representing a loss of 2.3% of the monthly cancer drug budget (9,780€/421,570€). During the program, a mean of 13 ± 2 of 1,626 preparations per month were destroyed, representing a mean loss of 1.5% ± 0,2% (5,815€/393,306€). The difference in mean loss was significant (p < 0.001) but not the number of destroyed preparations. Between Feb and June 2009, 55 seats were reallocated among the 99 available (median reallocation rate of 56% ± 6% [range:34%-68%]), which generated extra revenue of 5,000€ per month. Mean number of patients with a scheduled in-hospital visit per month was increased (21 ± 2 to 25 ± 2 prior to and during the pilot program). Conclusions: Despite an increase in the number of outpatients over the 1-year period, this pilot program allowed for better utilization of available slots in our medical oncology outpatient unit without requiring additional pharmacy and medical staff, and was consequently associated with extra revenue. No significant financial relationships to disclose.
Organ‐On‐Chip Platforms: Skin Diseases Modeling using Combined Tissue Engineering and Microfluidic Technologies (Adv. Healthcare Mater. 19/2016)
Authors: Mohammad Hossein Mohammadi, Behnaz Heidary Araghi, Vahid Beydaghi, Armin Geraili, Farshid Moradi, Parya Jafari, Mohsen Janmaleki, Karolina Papera Valente, Mohsen Akbari, Amir Sanati‐Nezhad
Journal: Advanced Healthcare Materials (2016)

Skin-on-chip platforms have integrated microfluidics, tissue engineering, biomaterials, and biosensors to recapitulate the skin structure and function, and develop skin grafts and biomimetic skin diseases. Skin-on-chip disease models can be potentially used in environmental safety testing, drug discovery, and pharmaceutical development. This scientific field is reviewed by Amir Sanati-Nezhad and co-workers on page 2459.
Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program
Authors: F. Giotta, A. Latorre, G. Monticelli, S. Oliva, D. Albano, G. Colucci
Journal: Journal of Clinical Oncology (2008)

12006 Background: Lapatinib, a TKI of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer progressing after trastuzumab-based therapy. The primary end point of this single arm, open label trial, was to offer the approval expanded access to lapatinib, in order to provide potential clinical benefit. Secondary objectives were progression free survival, overall survival and evaluation of serious adverse events. Methods: Women affected by locally advanced or metastatic breast cancer with ErbB2 overexpressing tumours, measurable disease and baseline left ventricular ejection fraction ≥ 50% that had progressed after regimens including anthracyclines, taxanes and trastuzumab were included. Since march 2007, 18 patients were enrolled. They received lapatinib at a dosage of 1,250 mg daily continuously plus capecitabine at a dosage of 2,000 mg/m2 on days 1 through 14 of a 21-day cycle. Cardiac function was assessed by ultrasonography at baseline and every three weeks, while objective response was evaluated every six weeks. Results: The principal characteristics of the 18 actually enrolled patients were: median age 54 years (range 42–63), median WHO performance status 1, all with visceral dominant and multiple disease site. To date 12 pts are evaluable for clinical response: 2 partial responses and 6 stable disease were observed; the remaining 4 pts progressed. Median duration of survival was 6+ months (range 4–9+). Toxicity consisted mainly in grade I-II asthenia in 5 pts and grade I-II hand-foot syndrome in 6 pts. Gastroenteric toxicity affected 4 pts. As to concer cardiac toxicity, two patients developed an asymptomatic decline of left ventricular ejection fraction below 50% and withdrawn the treatment. Conclusions: These preliminary data show the activity of lapatinib in previous heavily treated metastatic breast cancer. Further lapatinib-cytotoxic combinations are warranted. No significant financial relationships to disclose.
Impact of Cytogenetics on Outcome of Patients with MDS or Secondary AML Undergoing Allogeneic HSCT from HLA-Identical Siblings: A Retrospective Analysis of the EBMT-CLWP.
Authors: Francesco Onida, Ronald Brand, Anja van Biezen, Renee M. Barge, Leo F. Verdonck, Jurgen Finke, Dietrich Beelen, Rodrigo Martino, José M. Fernandez-Ranada, Dietger Niederwieser, Nicolaus Kröger, Theo de Witte
Journal: Blood (2006)
TCT-241 Endovascular hypothermia treatment dose-modulates cardioprotection in favor of 32°C target temperature before reperfusion in porcine myocardial infarction
Authors: Yoshiaki Mitsutake, Rajesh Dash, Fumiaki Ikeno, Wook Bum Pyun, Jennifer Lyons, Fady Dawoud, Uday Illindala, Alan Yeung
Journal: Journal of the American College of Cardiology (2015)